Search studies using keywords
5,026 Studies in the database containing data with -log p ≥ 0 (showing 161-180)
Pages: 1 2 3 4 5 6 7 8 9 10 >>
No data sets (in No Studies) added to Browser
Identifier Name Phenotype(s) Total p-values Related citationsAdd data sets to Browser Related data
HGVST4859 plus GWAS of Periodontitis 
  • Periodontitis (stage III/IV grade C)
8
HGVST4860 plus GWAS of Ovarian cancer 
  • Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel
  • Progression free survival in epithelial ovarian cancer
  • Progression free survival in serous epithelial ovarian cancer
  • Progression free survival in epithelial ovarian cancer treated with carboplatin and paclitaxel
90
HGVST4861 plus GWAS of Anti-drug antibodies 
  • Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1a subcutaneous)
  • Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; all treatment preparations)
  • Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1a subcutaneous and intramuscular)
  • Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1a subcutaneous and intramuscular)
  • Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1a subcutaneous)
  • Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1a subcutaneous)
  • Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; IFNβ-1b subcutaneous)
  • Neutralising antibody response to interferon beta therapy in multiple sclerosis (antibody titre; all treatment preparations)
  • Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; all treatment preparations)
  • Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1b subcutaneous)
  • Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1a subcutaneous and intramuscular)
  • Binding antibody response to interferon beta therapy in multiple sclerosis (antibody levels; IFNβ-1b subcutaneous)
21
HGVST4862 plus GWAS of Liver stiffness 
  • Liver stiffness changes at sustained virological response following antiviral therapy in HCV infection
13
HGVST4863 plus GWAS of Sarcoidosis 
  • Sarcoidosis
4
HGVST4864 plus GWAS of Kidney function 
  • Estimated glomerular filtration rate
2
HGVST4865 plus GWAS of Post-traumatic stress disorder 
  • Post-traumatic stress disorder
7
HGVST4866 plus GWAS of Cognitive impairment 
  • Hypotension and cognitive impairment
3
HGVST4867 plus GWAS of Bone mineral density 
  • Ultradistal forearm bone mineral density
32
HGVST4849 plus GWAS of Coronary artery disease 
  • Coronary artery disease
248
HGVST4850 plus GWAS of Systemic lupus erythematosus 
  • Systemic lupus erythematosus
14
HGVST4851 plus GWAS of Pancreatic ductal adenocarcinoma 
  • Pancreatic ductal adenocarcinoma
2
HGVST4852 plus GWAS of Premenopausal oestrone and progesterone 
  • Estrone-3-glucuronide levels
1
HGVST4853 plus GWAS of Serum uric acid 
  • Serum uric acid levels
34
HGVST4854 plus GWAS of Attention deficit hyperactivity disorder 
  • Attention deficit hyperactivity disorder (childhood)
  • Attention deficit hyperactivity disorder (persistent)
  • Attention deficit hyperactivity disorder
42
HGVST4855 plus GWAS of Systemic lupus erythematosus 
  • Systemic lupus erythematosus
232
HGVST4856 plus GWAS of Sortilin 
  • Sortilin levels
2
HGVST4857 plus GWAS of Lacunar stroke 
  • Lacunar stroke
10
HGVST4858 plus GWAS of Gut microbiome 
  • Actinobacteria id.403
  • genus Allisonella id.2174
  • Oxalobacteraceae id.2966
  • unknown family id.1000001214
  • Enterorhabdus id.820
  • Actinobacteria id.402
  • Anaerostipes id.1991
  • Pseudomonadaceae id.3718
  • Tyzzerella3 id.11335
  • Bacteroidales S24 7group id.11173
  • unknown genus id.1000001215
  • Bifidobacteriales id.432
  • Erysipelatoclostridium id.11381
  • Ruminococcus1 id.11373
  • Actinobacteria id.406
  • Candidatus Soleaferrea id.11350
  • Peptococcaceae id.2025
  • Actinobacteria id.419
  • Turicibacter id.2162
  • Ruminiclostridium6 id.11356
  • Streptococcaceae id.1850
  • Coprococcus1 id.11301
  • Peptococcaceae id.2024
  • Lachnospiraceae UCG 010 id.11330
  • Faecalibacterium id.2057
  • Actinobacteria id.401
  • Ruminococcaceae UCG009 id.11366
  • Oxalobacter id.2978
  • Actinobacteria id.407
  • Bifidobacterium id.436
  • Ruminococcaceae UCG013 id.11370
  • Actinobacteria id.408
  • Actinobacteria id.404
  • Bifidobacteriaceae id.433
  • Intestinibacter id.11345
  • Peptostreptococcaceae id.2042
  • Eubacterium coprostanoligenes group id.11375
  • Streptococcus id.1853
  • Gastranaerophilales id.1591
  • Ruminococcus torques group id.14377
  • Gut microbiota alpha diversity
  • Actinobacteria id.400
  • Peptococcus id.2037
  • Odoribacter id.952
  • Actinobacteria id.405
208
HGVST4841 plus GWAS of Alzheimer's disease 
  • Combined resilience (covariance of educational attainment with residual cognitive resilience)
  • Residual cognitive resilience
38